Advances in diabetes for the millennium: Diabetes and cholesterol CME

MedGenMed Medscape General Medicine

Volumn 6, Issue 3 SUPPL., 2004, Pages

  Rendell, Marc ^a,b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Rose Salter Medical Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; HEART PROTECTION; HEMATURIA; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY TUBULE DISORDER; LIVER TOXICITY; MEDICAL EDUCATION; MORTALITY; MYOPATHY; PERIPHERAL NEUROPATHY; PROTEINURIA; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; BLOOD; REVIEW;

CHOLESTEROL; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 27544498074     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Pearson TA, Swan HJ. Lipid lowering: the case for identifying and treating the high-risk patient. Cardiol Clin. 1996;14:117-130.
2. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J. 1985;110:1100-1107.
3. Wilson PW, Castelli WP, Kannel WB. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol. 1987;59:91G-94G.
4. Brook JG, Rifkind BM. Cholesterol and coronary heart disease prevention -- a transatlantic consensus. Eur Heart J. 1989;10:702-711.
5. Arnett DK, McGovern PG, Jacobs DR Jr, et al. Fifteen-year trends in cardiovascular risk factors (1980-1982 through 1995-1997): the Minnesota Heart Survey. Am J Epidemiol. 2002;156:929-935.
6. Werner RM, Pearson TA. LDL-cholesterol: a risk factor for coronary artery disease - from epidemiology to clinical trials. Can J Cardiol. 1998;14(supplB):3B.
7. Grundy SM; National Cholesterol Education Program (NCEP)-The National Cholesterol Guidelines in 2001, Adult Treatment Panel (ATP) III. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002;90:11i-21i.
8. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41:1480-1481.
9. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
10. Ong HT. Protecting the heart: a practical review of the statin studies. Medscape General Medicine. 2002; 4. Available at: http://www.medscape.com/viewarticle/445150 Accessed August 2, 2004.
11. Tonkin AM. Clinical relevance of statins: their role in secondary prevention. Atheroscler Suppl. 2001;2:21-25.
12. Luria MH, Erel J, Sapoznikov D, Gotsman MS. Cardiovascular risk factor clustering and ratio of total cholesterol to high-density lipoprotein cholesterol in angiographically documented coronary artery disease. Am J Cardiol. 1991;67:31-36.
13. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol. 1992;70:733-737.
14. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124:S11-S20.
15. West MJ, White HD, Simes RJ, et al. Risk factors for non-haemorrhagic stroke in patients with coronary heart disease and the effect of lipid-modifying therapy with pravastatin. J Hypertens. 2002;20:2513-2517.
16. Aronow WS, Ahn C, Gutstein H. Reduction of new coronary events and new atherothrombotic brain infarction in older persons with diabetes mellitus, prior myocardial infarction, and serum low-density lipoprotein cholesterol >/= 125 mg/dl treated with statins. J Gerontol A Biol Sci Med Sci. 2002;57:M747-M750.
17. Jousilahti P, Toumilehto J, Vartiainen E, et al. Importance of risk factor clustering in coronary heart disease mortality and incidence in eastern Finland. J Cardiovasc Risk. 1995;2:63-70.
18. Esper RJ. The role of lipid-lowering therapy in multiple risk factor management. Drugs. 1998;56(suppl1):1-7.
19. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care. 2000;23:962-968.
20. Natali A, Vichi S, Landi P, Severi S, L'Abbate A, Ferrannini E. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia. 2000;43:632-641.
21. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;288:955.
22. Behar S, Boyko V, Reicher-Reiss H, Goldbourt U. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial. Am Heart J. 1997;133:290-296.
23. Herlitz J, Wognsen GB, Karlson BW, et al. Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis. 2000;11:339-346.
24. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992;15:820-825.
25. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-1622.
26. Long Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
27. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98:2513-2519.
28. Burton JR, Teo KK, Buller CE, et al. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT). Can J Cardiol. 2003;19:487-491.
29. Pedersen TR. Coronary artery disease: the Scandinavian Simvastatin Survival Study experience. Am J Cardiol. 1998;82:53T-56T.
30. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med. 1999;159:2661-2667.
31. Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation. 2002;105:1424-1428.
32. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-2016.
33. Stulc T, Kasalova Z, Prazny M, Vrablik M, Skrha J, Ceska R. Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment. Physiol Res. 2003;52:439-445.
34. Chowdhury TA, Hopkins D, Dodson PM, Vafidis GC. The role of serum lipids in exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye. 2002;16:689-693.
35. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56:1-11.
36. Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol. 2002;23:263-277.
37. Sowers JR. Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndrome. Am J Cardiol. 2003;91:14B-22B.
38. Lee IT, Sheu WH, Lin SY, Lee WJ, Song YM, Liu HC. Simvastatin reduces plasma concentration of high-sensitivity C-reactive protein in type 2 diabetic patients with hyperlipidemia. J Diabetes Complications. 2002;16:382-385.
39. Skinner JS, Farrer M, Albers CJ, Adams PC. Risk factor control five years after coronary bypass grafting. J R Coll Physicians Lond. 1996;30:136-141.
40. Smith NL, Savage PJ, Heckbert SR, et al. Glucose, blood pressure, and lipid control in older people with and without diabetes mellitus: the Cardiovascular Health Study. J Am Geriatr Soc. 2002;50:581-583.
41. Charpentier G, Genes N, Vaur L, et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey. Diabetes Metab. 2003;29:152-158.
42. Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, Pogach L. Disparities in use of lipid-lowering medications among people with type 2 diabetes mellitus. Arch Intern Med. 2003;163:922-928.
43. Massing MW, Foley KA, Sueta CA, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care. 2003;26:991-997.
44. Wandell PE, Gafvels C. Drug prescription in men and women with type 2 diabetes in Stockholm in 1995 and 2001: change over time. Eur J Clin Pharmacol. 2002;58:547-553.
45. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-1690.
46. Andrejak M, Gras V, Massy ZA, Caron J. Adverse effects of statins. Therapie. 2003;58:77-83.
47. Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002;24:2126-2136.
48. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
49. Jacobson TA. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opin Drug Saf. 2003;2:269-286.
50. Farmer JA. Statins and myotoxicity. Curr Atheroscler Rep. 2003;5:96-100.
51. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. J Nephrol. 2002;15:690-695.
52. Andrade SE, Donahue JG, Chan KA, Watson DJ, Platt R. Liver function testing in patients on HMG-CoA reductase inhibitors. Pharmacoepidemiol Drug Saf. 2003;12:307-313.
53. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163:688-692.
54. Backes JM, Howard PA. Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother. 2003;37:274-278.
55. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-160.
56. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003;92:23K-29K.
57. Crestor (rosuvastatin calcium) Prescribing Information. Wilmington, Del: AstraZeneca Pharmaceuticals LP, 2003.